Fondazione Michelangelo
avanzamento dello studio e cura dei tumori

XIV MICHELANGELO SEMINAR

November 7, 2014
Milan, Hotel Michelangelo
Piazza Luigi di Savoia, 6

Preliminary Program

h 13.00 - 19.00

FACULTY

- **Eitan Amir**
  Toronto, Canada
- **Mitch Dowsett**
  London, United Kingdom
- **Luca Gianni**
  Ospedale San Raffaele IRCCS, Milan, Italy
- **Richard Gray**
  Oxford, United Kingdom
- **Norman Wolmark**
  Pittsburgh, USA

Late and later relapses and sequelae: the dilemma of endocrine treatment duration, compliance and treatment tailoring

Hormone receptors positive breast cancers are molecularly and clinically heterogeneous diseases. The heterogeneity leads to diverse risks of recurrence and variable treatment benefit. One of the well-characterized clinical features of hormone receptor positive breast cancer is the long lasting risk of relapse that persists for more than a decade. To reduce the risk of late recurrences, endocrine treatments for period longer than the standard 5 years have been assessed in clinical trials.

Extended endocrine therapy with aromatase inhibitors after 5 years of tamoxifen led to significant reduction of risk of relapse and death. In addition, two large randomized trials have recently demonstrated that 10 years of adjuvant tamoxifen produced a small but significant reduction of recurrences and deaths compared to the conventional duration of 5 years. In the light of these evidence the clinicians cannot avoid to address the question whether every woman with a hormone-receptor positive breast cancer should receive endocrine adjuvant therapy for 10 or even more years.

No matter how large, the benefit of any treatment is restricted to a fraction of patients, and must be weighted against the side effects, especially of such prolonged chronic therapy. The identification of patients who will actually benefit from extended endocrine drugs is therefore very relevant to tailor the prescription of tamoxifen or aromatase inhibitors beyond 5 years, and to avoid it in patients who will not derive additional benefit. A similar ability to predict the risk and the extent of side effects would provide a dependable assessment of individual risk-to-benefit ratio, and eventually improve the compliance in those selected women who deserve extended endocrine treatment.

These topics will be the focus of the XIV Michelangelo Seminar to be held in Milan on November 7, 2014.

Endorsements

AIOM Associazione Italiana di Oncologia Medica

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE
European Society for Medical Oncology

Alleanza contro il cancro

ASCO
American Society of Clinical Oncology
Making a world of difference in cancer care

This program has the American Society of Clinical Oncology's approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment. ASCO® is a registered trademark of the American Society of Clinical Oncology® Used with permission. This is not an ASCO sponsored event.

FONDAZIONE MICHELANGELO
avanzamento dello studio e cura dei tumori

XIV MICHELANGELO SEMINAR

Preliminary Program

- *Welcome address*
  Luca Gianni - *Milano, Italy*

- **Extended endocrine treatment - EBCTCG meta-analyses**
  Richard Gray - *Oxford, United Kingdom*

- **Aromatase inhibitors as extended endocrine treatment**
  Norman Wolmark - *Pittsburgh, USA*

- **Tailoring of extended endocrine treatments: does one size fit all?**
  Mitch Dowsett - *London, United Kingdom*

- **Toxicities of and compliance with endocrine therapy**
  Eitan Amir - *Toronto, Canada*

- **Expert panel discussion**
  Luca Gianni *(Milano, Italy)*, **Richard Gray** *(Oxford, United Kingdom)*,
  Norman Wolmark *(Pittsburg, USA)*, **Mitch Dowsett** *(London, United Kingdom)*,
  Eitan Amir *(Toronto, Canada)*

- *Conclusion*

General information

- **Seminar Venue**
  Hotel Michelangelo Piazza Luigi di Savoia, 6
  Meeting room: Michelangelo (ground floor)
  M2 - M3 Central Station

- **CME Accreditation** for the competent bodies (6 credits – n. 210/105851)

- **Official Language**
  The official language will be English. Simultaneous translation will be provided

- **Application**
  Attendance is free of charge, however application is compulsory.
  Please send the application form to michelangelo@newaurameeting.it until 31st October 2014

- **Accommodation**
  To require hotel accommodation in Milan, please fill in the registration form in attach; for further information, contact the Organizing Secretary to michelangelo@newaurameeting.it

Scientific Secretariat
- **Gianni Bonadonna** (Chair)
- **Giampaolo Bianchini**
- **Angelica Fasolo**

Fondazione Michelangelo
Via A. Bertani, 14 - 20154 Milano, Italy
Phone +39 02 87086421 - Fax +39 02 87086449

E-mail: segreteria@fondazionemichelangelo.org
www.fondazionemichelangelo.org

Organizing Secretariat
New Aurameeting Srl
Via Rocca d'Anfo, 7- 20161 Milan, Italy
Phone: +39 02 66203390
Fax: +39 02 66200418
E-mail: michelangelo@newaurameeting.it
www.newaurameeting.it

FONDAZIONE MICHELANGELO
avanzamento dello studio e cura dei tumori

XIV MICHELANGELO SEMINAR

November 7, 2014
Milan, Hotel Michelangelo
Piazza Luigi di Savoia, 6

Application Form

Please send to New Aurameeting srl
Via Rocca d'Anfo 7, 20161 Milan – Fax: + 39.02.66200418
e-mail: michelangelo@newaurameeting.it until 31st October 2014

Title: ❑ Dr. ❑ Prof. ❑ Mr. ❑ Mrs.

Family Name

First Name

Company/Institute

Address

ZIP Code City

Country

e-mail

Phone Fax

Attendant of Oncologia Medica – Scuola di Specializzazione (Università degli Studi di Milano): ❑ YES ❑ NO

To require Hotel Accommodation in Milan please fill with the following compulsory information:

Check-in: Check-out N° nights

Hotel Category: ❑ 3 stars ❑ 4 stars

In Conformity with the legislative decree 196/2003, New Aurameeting will use the personal data supplied only for communications related to the services offered and for administrative processes. For Right of access to personal data and other rights (Art. 7) please write to New Aurameeting Srl, Via Rocca d'Anfo 7, 20161 Milano – info@newaurameeting.it

Useful Information:

XIV Michelangelo Seminar
Late and later relapses and sequelae: the dilemma of endocrine treatment duration, compliance and treatment tailoring
November 7, 2014

- *Seminar Venue: Hotel Michelangelo, Piazza Luigi di Savoia, 6*
- *Meeting room: Michelangelo (ground floor)*
- *CME Accreditation required for the competent bodies*
- *Deadline for registration: 31st October 2014*
- *Official Language: English (simultaneous translation will be provided)*
- *Attendance is free, however application is compulsory for organizing reason.*

Travel Information to reach the Congress Venue:

By public transport

Metro M2 - M3 Stop Central Station
Coming out of the subway station, follow the signs to Piazza Luigi di Savoia. The Hotel is just a few meters from the taxi station, crossing the street, on the sidewalk in front of the station.

From the airports

Malpensa Airport
Malpensa Express Train or Malpensa shuttle to Central Station departing every 20/30 minutes.

Linate Airport
Bus 73 to S. Babila then
Metro M1 direction Bisceglie / Rho-Fiera - 1 stop (station Duomo) then
Metro M3 (yellow line) direction Comasina – 4 stop (Central Station FS)

Orio al Serio Airport
Coach "Orio Shuttle" or "Autostradale" to Milan Central Station FS